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ABSTRACT
Objectives To determine the prevalence of cardiovascular
disease (CVD) risk factors and explore associations with
high-sensitivity cardiac troponin I (hscTnI) and high-
sensitivity C-reactive protein (hsCRP) in people living with
HIV (PLHIV) in Kenya.
Design Pilot cross-sectional study.
Setting Data were collected from community HIV clinics
across two sites in Nairobi, Kenya, from July 2019 to May
2020.
Participants Convenience sample of 200 PLHIV (≥30
years with no prior history of CVD).
Outcome measures Prevalence of cardiovascular risk
factors and its association with hsTnI and hsCRP levels.
Results Across 200 PLHIV (median age 46 years, IQR 38–53;
61% women), the prevalence of hypercholesterolaemia
(total cholesterol >6.1 mmol/L) and hypertension were 19%
(n=30/199) and 30% (n=60/200), respectively. Smoking and
diabetes prevalence was 3% (n=5/200) and 4% (n=7/200).
HscTnI was below the limit of quantification (<2.5 ng/L) in 65%
(n=109/169). High (>3 mg/L), intermediate (1–3 mg/L) and low
(<1 mg/L) hsCRP levels were found in 38% (n=75/198), 33%
(n=65/198) and 29% (n=58/198), respectively. Framingham
laboratory-based risk scores classified 83% of PLHIV at
low risk with 12% and 5% at intermediate and high risk,
respectively. Older age (adjusted OR (aOR) per year increase
1.05, 95% CI 1.01 to 1.08) and systolic blood pressure (140–
159 mm Hg (aOR 2.96; 95% CI 1.09 to 7.90) and >160 mm
Hg (aOR 4.68, 95% CI 1.55 to 14) compared with <140 mm
Hg) were associated with hscTnI levels. No associations were
observed between hsCRP and CVD risk factors.
Conclusion The majority of PLHIV—using traditional
risk estimation systems—have a low estimated
CVD risk likely reflecting a younger aged population
predominantly consisting of women. Hypertension and
hypercholesterolaemia were common while smoking and
diabetes rates remained low. While hscTnI values were
associated with increasing age and raised blood pressure,
no associations between hsCRP levels and traditional
cardiovascular risk factors were observed.

INTRODUCTION
More than 35 million people are infected
with the HIV with two-thirds being resident

STRENGTHS AND LIMITATIONS OF THIS STUDY
⇒ Involvement of people living with HIV from a low-

⇒

⇒

⇒
⇒

income and middle-income settings and from distinct socioeconomic backgrounds.
Assessment of relatively novel biochemical markers
of cardiovascular risk alongside more traditional
cardiovascular risk factors.
Due to the cross-sectional design, we were unable
to evaluate the associations between novel biochemical markers and future cardiovascular events.
The study population was from an urban setting, so
generalisability to rural settings is limited.
There was no age-matched and sex-matched uninfected control group.

in sub-Saharan Africa.1 Although the global
incidence for HIV has stabilised, the wide
availability of combined antiretroviral
therapy (ART) has dramatically improved
survival, resulting in a steady increase in
prevalence over the last two decades.2 3 This
improvement in survival has been primarily
attributed to a reduction in opportunistic
infections especially in low-income and lower-
middle-income nations. Conversely, mortality
due to non-communicable illnesses especially
cardiovascular disease (CVD) has been rising
and now account for the majority of deaths in
people living with HIV (PLHIV).1 4–7
PLHIV-
based on studies in high-
income
countries—have a higher risk of CVD.8 9
Despite this higher risk, previous studies have
indicated that PLHIV in sub-Saharan Africa
have a lower prevalence of traditional
cardiovascular risk factors in comparison to
uninfected individuals.8 10 Strategies to risk
stratify and mitigate CVD in this population
is now urgently required but is challenging
in resource limited nations11 and it remains
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METHODS
Study setting and population
This was a pilot, prospective, cross-
sectional study of
PLHIV ≥30 years in Nairobi, Kenya. Population sample
size was determined based on the fixed recruitment period
from July 2019 to May 2020. Patients were recruited based
on convenient sampling and invited to participate as long
as they received care at the two clinical sites (Aga Khan
University Hospital and Coptic Hope Center for Infectious Diseases) where the researchers and their research
teams were based. Aga Khan University Hospital is a fee-
for-service tertiary care centre generally serving a more
affluent population while the Coptic Hope Center for
Infectious Diseases is a Centre of Disease Control President’s Emergency Plan For AIDS Relief funded institution to provide free ART to Kenyans who are unable to
afford HIV care and treatment.13 Participants with known
CVD (previous myocardial infarction or stroke) were
excluded.
Study procedures and blood sampling
All participants completed a standardised questionnaire
to capture data on demographics, including self-reported
cardiovascular risk factors, medical history, current medication and HIV factors including time since diagnosis.
Data were captured on handheld devices electronically.
Anthropometric and haemodynamic data including
office blood pressure, height, weight and heart rate were
captured.

limit of quantification of 2.5 ng/L. The upper reference
limit 99th centile was determined in 2007 samples from
healthy individuals as 34 ng/L in women, and 53 ng/L in
men, with a single threshold of 45 ng/L. In the reference
range population, 75% of patients had values greater
than the limit of detection. The level where the interassay
coefficient of variation is <10% is 6 ng/L.14
HsCRP
The Siemens Atellica hsCRP assay was used to measure
hsCRP levels in stored serum. The assay range is from
0.1 to 50 mg/L with a coefficient of variation of 6.8% at
1.16 mg/L.15
Study definitions
Traditional cardiovascular risk factors were defined as
those routinely measured in cardiovascular risk estimation systems and include basic anthropometry, diabetes
and smoking status, lipid profile and arterial blood pressure assessment. Body mass index was calculated from
measured height and weight and classified as normal
weight (18.5–24.9 kg/m2), overweight (25.0–29.9 kg/m2)
and obese (equal to or greater than 30.0 kg/m2). Current
or past smoking history was self-reported by participants.
Hypertension was defined as self-reported hypertension
or measured systolic blood pressure (SBP) ≥140 mm
Hg or diastolic blood pressure (DBP) ≥90 mm Hg, or
physician-
prescribed blood pressure-
lowering medications.16 Dyslipidaemia was defined as a self-
reported
history. Hypercholesterolaemia was defined as a total
cholesterol ≥6.21 mmol/L. A high low-
density lipoprotein (LDL) was defined as levels >4.1 mmol/L.17 Diabetes
mellitus was defined as self-reported type 1 or 2 diabetes
mellitus. Patients, in whom HbA1c was measured, were
classified as those with high (≥6.5%), intermediate
(5.7%–6.4%) and low levels (<5.7%).18 The hsCRP was
categorised as low (<1 mg/L), intermediate (1–3 mg/L)
or high (>3 mg/L).19 HscTnI levels were categorised as
below the limit of quantification (2.5 ng/L), above the
limit of quantification but below the 99th centile upper
reference limit and above the 99th centile upper reference limit (45 ng/L).20

High-sensitivity troponin I
The Siemens Atellica IM High Sensitivity Troponin I
assay (Siemens Healthineers) is a three-
site sandwich
immunoassay with a limit of detection of 1.6 ng/L and

Statistical analysis
Baseline demographics, clinical and lifestyle variables,
laboratory biomarkers including markers of myocardial
injury, inflammation, glycaemic control and lipid profiles
were summarised overall and stratified by gender. Continuous variables were reported as median and IQR, while
the categorical variables were summarised as frequencies
and percentages. Statistical differences between groups
were assessed using Pearson’s χ2 test or Fisher’s exact
test and unpaired two-samples Wilcoxon test or Student’s
t-test as indicated. Sex-specific Framingham laboratory-
based risk equations were used to quantify the estimated 10-year CVD risk for each study participant. The
equation used age, gender, smoking status, use of anti-
hypertensive medications, prevalent diabetes and SBP.
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Blood sampling
Blood samples were obtained from participants through
standard venepuncture. Basic clinical chemistry and
haematology was performed. This included assessment
of renal function, glycaemic control, non-
fasted lipid
profiles, high-sensitivity cardiac troponin I (hscTnI) and
high-sensitivity C-reactive protein (hsCRP). Given laboratory constraints, haemoglobin A1c (HbA1c) and haematology was only measured in the Aga Khan University
Hospital population.
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unclear on optimal approaches with recommendations
differing across regions globally.12
In this cross-sectional pilot study of PLHIV in Kenya, we
evaluate the prevalence of traditional cardiovascular risk
factors and the distribution of estimated cardiovascular
risk using traditional risk scores. We further explore the
distribution of markers of myocardial injury and inflammation in this population. Our additional objectives are
to evaluate the logistic feasibility, including recruitment
rates, for a full-scale study investigating mechanisms in
HIV-associated CVD.

Open access

Sex
Characteristics

All patients (n=200)

Females (n=121)

Males (n=79)

P value†

Age, median (Q1, Q3), years
Years of education, median (Q1, Q3)

45.5 (37.7, 52.6)
14.0 (12.0, 16.0)

44.2 (37.3, 50.5)
14.0 (12.0, 16.0)

47.3 (38.0, 53.1)
15.0 (12.0, 16.5)

0.206
0.174

 Primary/none/do not know, %

30/200 (15.0)

18/121 (14.9)

12/79 (15.2)

0.825

 Secondary, %

45/200 (22.5)

29/121 (24.0)

16/79 (20.3)

 Higher education/university, %

125/200 (62.5)

74/121 (61.2)

51/79 (64.6)

 Married (monogamous/polygamous), %

128/200 (64.0)

64/121 (52.9)

64/79 (81.0)

 Single

26/200 (13.0)

23/121 (19.0)

3/79 (3.8)

 Separated/widowed/divorced/refused/
cohabiting/others, %

46/200 (23.0)

34/121 (28.1)

12/79 (15.2)

 Salaried Job or self-employed, %

180/200 (90.0)

105/121 (86.8)

75/79 (94.9)

 Unemployed/housewife/retiree, %

13/200 (6.5)

11/121 (9.1)

2/79 (2.5)

 Casual labourer, %

7/200 (3.5)

5/121 (4.1)

2/79 (2.5)

 <15 001 KES, %

34/198 (17.2)

26/119 (21.8)

8/79 (10.1)

 >15 001 KES, %

164/198 (82.8)

93/119 (78.2)

71/79 (89.9)

 Current smoker, %

5/200 (2.5)

2/121 (1.7)

3/79 (3.8)

 Ex-smoker, %

44/200 (22.0)

11/121 (9.1)

33/79 (41.8)

 Never smoker, %

151/200 (75.5)

108/121 (89.3)

43/79 (54.4)

 Diabetes, %

7/200 (3.5)

4/121 (3.3)

3/79 (3.8)

0.661

 Self-reported hypertension,‡ %

44/200 (22.0)

30/121 (24.8)

14/79 (17.7)

0.315

 Cumulative hypertension,§ %

60/200 (30.0)

34/121 (28.1)

26/79 (32.9)

0.570

 Self-reported dyslipidaemia, %

1/197 (0.5)

1/119 (0.8)

0/78 (0.0)

0.153

 Chronic kidney disease, %

2/200 (1.0)

1/121 (0.8)

1/79 (1.3)

0.863

 Time since (months) HIV infection, median 143.0 (59.0, 191.0)
(Q1, Q3)

144.0 (62.0, 191.0)

131.0 (56.5, 191.0)

0.574

 Currently on ART, %

195/200 (97.5)

119/121 (98.3)

76/79 (96.2)

0.385

 Malaria, %

21/200 (10.5)

10/121 (8.3)

11/79 (13.9)

0.298

 Tuberculosis, %

12/200 (6.0)

7/121 (5.8)

5/79 (6.3)

1.000

 Body mass index, BMI (Kg/m2), median
(Q1, Q3)

26.8 (23.4, 30.8)

27.9 (23.8, 32.3)

26.0 (23.2, 29.6)

0.010

 BMI <25, %

71/200 (35.5)

37/121 (30.6)

34/79 (43.0)

0.100

 BMI 25–29, %

71/200 (35.5)

43/121 (35.5)

41/79 (33.9)

 BMI >30, %
 Systolic blood pressure (mm Hg), median
(Q1, Q3), n=200

58/200 (29.0)
120.0 (110.0, 133.0)

41/121 (33.9)
120.0 (110.0, 130.0)

17/79 (21.5)
122.0 (111.5, 133.0) 0.272

Highest level of education attained

Marital status
<0.001

Employment status
0.148

Household income per month
0.051

Cardiovascular risk factors
Smoking
<0.001

HIV

Medical history

Clinical characteristics

Continued
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Table 1 Baseline demographics and clinical characteristics*

Open access

Sex
Characteristics

All patients (n=200)

Females (n=121)

Males (n=79)

P value†

 SBP <130 mm Hg, %

136/200 (68.0)

86/121 (71.1)

50/79 (63.3)

0.173

 SBP 130–139 mm Hg, %

30/200 (15.0)

19/121 (15.7)

11/79 (13.9)

 SBP 140–159 mm Hg, %

19/200 (9.5)

7/121 (5.8)

12/79 (15.2)

 SBP >160 mm Hg, %

15/200 (7.5)

9/121 (7.4)

6/79 (7.6)

 Diastolic blood pressure (mm Hg), median 78.0 (71.0, 85.0)
(Q1, Q3), n=200

77.0 (71.0, 84.0)

80.0 (72.0, 85.0)

0.301

 DBP <85 mm Hg, %

149/200 (74.5)

92/121 (76.0)

57/79 (72.2)

0.417

 DBP 85–89 mm Hg, %

22/200 (11.0)

10/121 (8.3)

12/79 (15.2)

 DBP 90–99, %

17/200 (8.5)

12/121 (9.9)

5/79 (6.3)

 DBP >100, %

12/200 (6.0)

7/121 (5.8)

5/79 (6.3)

 Heart rate (bpm) median (Q1, Q3)

78.0 (74.0, 82.0)

76.5 (74.8, 84.2)

78.0 (72.0, 81.0)

0.474

Current cardiovascular medications
 RAAS modulators, %

16/200 (8.0)

11/121 (9.1)

5/79 (6.3)

0.662

 Calcium channel blockers, %

8/200 (4.0)

5/121 (4.1)

3/79 (3.8)

1.000

 Beta-blockers, %

8/200 (4.0)

5/121 (4.1)

3/79 (3.8)

1.000

 Diuretics, %
 Statins, %

10/200 (5.0)
2/200 (1.0)

8/121 (6.6)
1/121 (0.8)

2/79 (2.5)
1/79 (1.3)

0.321
1.000

*Number of patients may not sum to the corresponding column totals where there are missing data for the variable.
†P value from χ2 test or Fisher’s exact test for categorical variables and unpaired two-sample Wilcoxon test for continuous variables, two-
sided; bold p values indicate statistical significance (p<0.05).
‡Self-reported physician-diagnosed hypertension.
§Self-reported hypertension or measured systolic blood pressure (SBP) ≥140 mm Hg or diastolic blood pressure (DBP) ≥90 mm Hg, or
physician-prescribed blood pressure-lowering medications.
ART, antiretroviral therapy; HDL, high density lipoprotein; KES, Kenya shillings currency code; RAAS, Renin–angiotensin–aldosterone system.

were constructed on complete cases with no imputation.
All analysis was carried out in R (V.4.1.2).
Patients were enrolled only after providing written
informed consent prior to participation. Site approval
was obtained from the Coptic Hope Center for Infectious Diseases in Nairobi. The research was carried out
in accordance with the Helsinki Declaration’s principles.

The risk estimations were computed according to algorithms accessed at https://framinghamheartstudy.org/
fhs-risk-functions/cardiovascular-disease-10-year-risk/.
Predicted cardiovascular event risk percentage over the
next 10 years was classified as low (< 10%), intermediate
(10%–20%) and high risk (> 20%).
In further analysis, we evaluated the relationship
between baseline markers of myocardial injury and
inflammation and traditional cardiovascular risk factors.
We calculated the 25th and 75th percentiles of observed
hscTnI data and ordinally scaled it as <2.50 ng/L (undetectable), 2.50–3.02 ng/L, 3.02–7.12 ng/L, ≥7.12 ng/L
given the skewness of the variable.21 Three multivariable
ordinal (cumulative logit) models and linear regression
models with hscTnI and hsCRP as the response variable,
respectively, were fitted. The independent variables were
age, sex and cardiovascular risk factors. Model I adjusted
for age per year increase, sex, study site as a surrogate
for socioeconomic status and creatinine. Model II additionally adjusted for hypertension, diabetes and smoking
status (never smoker, former smoker, current smoker).
Model III adjusted for variables in Model I plus SBP
(SBP <130 mm Hg, SBP 130–139 mm Hg, SBP 140–159 mm
Hg, SBP >160 mm Hg) and hsCRP or hscTnI. Models

RESULTS
Two hundred patients (median age 46 years (IQR
38–53 years), 61% women) were recruited in this
cross-
sectional study consisting (online supplemental figure S1). Prevalence of smoking was 2.5%
across the cohort and higher in men compared with
women. Hypertension was the most common cardiovascular risk factor at 30% with rates higher in men
(33%) compared with women (28%). Self-reported
dyslipidaemia was low at 0.5% but much higher when
classified according to a total cholesterol concentration >6.1 mmol/L (19%). The prevalence of elevated
LDL ≥4.2 mmol/L was 14%. Seventeen per cent of the
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No patient involvement.
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Table 1 Continued
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Sex
Characteristics

All patients (n=200)

Females (n=121)

Males (n=79)

P value†

Creatinine, median (Q1, Q3), n=197
Urea, median (Q1, Q3), n=196

85.0 (73.0, 101.0)
3.7 (3.1, 4.6)

77.5 (69.0, 89.3)
3.6 (3.0, 4.3)

99.0 (89.0, 113.0)
3.8 (3.2, 5.0)

<0.001
0.013

Haemoglobin, mean (SD), n=98*‡

14.01 (2.06)

12.90 (1.77)

15.31 (1.55)

<0.001

Glucose, median (Q1, Q3), n=197

4.8 (4.4, 5.3)

4.8 (4.3, 5.3)

4.9 (4.5, 5.3)

0.169

HbA1c, median (Q1, Q3), n=98*‡

5.6 (5.4, 5.9)

5.6 (5.4, 5.8)

5.8 (5.4, 6.1)

0.013

HbA1c <5.7, %

50/98 (51.0)

34/53 (64.2)

16/45 (35.6)

0.004

HbA1c 5.7–6.4, %

45/98 (45.9)

19/53 (35.8)

26/45 (57.8)

HbA1c ≥6.5, %

3/98 (3.1)

0/53 (0.0)

3/45 (6.7)

 Total cholesterol, median (Q1, Q3), n=196

4.6 (3.9, 5.1)

4.7 (3.9, 5.2)

4.5 (3.9, 5.1)

0.706

 TC <4.7, %

107/196 (54.6)

59/118 (50.0)

48/78 (61.5)

0.393

 TC 4.8–5.1, %

22/196 (11.2)

15/118 (12.7)

7/78 (9.0)

 TC 5.2–6.1, %

30/196 (15.3)

21/118 (17.8)

9/78 (11.5)

 TC ≥6.2, %

37/196 (18.9)

23/118 (19.5)

14/78 (17.9)

 LDL, median (Q1, Q3), n=196

3.0 (2.3, 3.6)

3.0 (2.4, 3.7)

3.0 (2.3, 3.5)

0.747

 LDL <2.6

75/196 (38.3)

46/118 (39.0)

29/78 (37.2)

0.619

 LDL 2.6–3.3

53/196 (27.0)

30/118 (25.4)

23/78 (29.5)

 LDL 3.4–4.1

41/196 (20.9)

23/118 (19.5)

18/78 (23.1)

 LDL ≥4.2

27/196 (13.8)

19/118 (16.1)

8/78 (10.3)

 HDL, median (Q1, Q3), n=196

1.2 (1.0, 1.5)

1.2 (1.1, 1.5)

1.1 (1.0, 1.3)

0.001

 Trigylcerides, median (Q1, Q3), n=196

1.4 (0.9, 2.0)

1.2 (0.9, 1.7)

1.7 (1.0, 2.7)

0.0005

 Trig <1.7

123/196 (62.8)

86/118 (72.9)

37/78 (47.4)

<0.0001

 Trig 1.7–2.2

32/196 (16.3)

19/118 (16.1)

13/78 (16.7)

 Trig >2.3

41/196 (20.9)

13/118 (11.0)

28/78 (35.9)

 High sensitivity troponin I, median (Q1, Q3),
n=169

2.5 (2.5, 3.0)

2.5 (2.5, 2.5)

2.7 (2.5, 3.8)

<0.0001

 hscTnI <2.5 ng/L, %

109/169 (64.5)

78/103 (75.7)

31/66 (47.0)

<0.001

Lipid profiles

Cardiac and inflammatory biomarkers

 hscTnI 2.5–45 ng/L

59/169 (34.9)

24/103 (23.3)

35/66 (53.0)

 hscTnI ≥45 ng/L

1/169 (0.6)

1/103 (1.0)

0/66 (0.0)

 High-sensitivity CRP, median (Q1, Q3), n=198 2.0 (0.8, 4.2)

2.2 (0.9, 4.5)

1.5 (0.8, 3.8)

 hsCRP <1 mg/L

58/198 (29.3)

31/120 (25.8)

27/78 (34.6)

 hsCRP 1–3 mg/L
 hsCRP >3 mg/L

65/198 (32.8)
75/198 (37.9)

39/120 (32.5)
50/120 (41.7)

26/78 (33.3)
25/78 (32.1)

0.144
0.300

*Number of patients may not sum to the corresponding column totals where there are missing data for the laboratory marker.
†P value from χ2 test or Fisher’s exact test for categorical variables and unpaired two-sample Wilcoxon test or Student’s t-test for continuous
variables, two-sided; bold p values indicate statistical significance (p<0.05).
‡* Haemoglobin and haemoglobin A1c (HbA1c) summaries are from Aga Khan University Hospital only.
hsCRP, high-sensitivity C-reactive protein ; hscTnI, high-sensitivity cardiac troponin I; LDL, low-density lipoprotein .

population had a SBP ≥140 mm Hg and 15% of the
population had a DBP ≥90 mm Hg. Obesity rates were
high with 29% considered obese and 36% overweight.
Obesity rates were higher in women at 34% compared
with men (22%). Prior history of malaria and tuberculosis remained high at 11% and 6%, respectively.
Over 90% of participants were receiving ART and

median duration of diagnosis to study recruitment
was 12 years (tables 1 and 2). Given differences in the
population served at Aga Khan University and Coptic
hospitals, we observed important differences in baseline characteristics. Patient treated at Coptic hospital
has lower income levels and higher rates of elevated
blood pressure (online supplemental table S1).
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Table 2 Biochemistry and haematology*

Open access

Framingham risk score classification (lipid)†

P value for trend‡

Variable

Low

Intermediate

High

Increasing Two-sided

Males
All (%)

58 (73.4)

14 (17.7)

7 (8.9)

 

 

Smoking

 

 

 

–

0.503

 Current smoker, %

3/58 (5.2)

0/14 (0.0)

0/7 (0.0)

 Ex-smoker, %

22/58 (37.9)

6/14 (42.9)

5/7 (71.4)

 Never smoker, %

33/58 (56.9)

8/14 (57.1)

2/7 (28.6)

 Diabetes, %

3/58 (5.2)

0/14 (0.0)

0/7 (0.0)

0.163

0.326

 Hypertension,§ %

12/58 (20.7)

6/14 (42.9)

7/7 (100.0)

<0.001

<0.001

 Hyperlipidaemia, %

0/58 (0.0)

0/13 (0.0)

0/7 (0.0)

–

–

Lipid profiles

 

 

 

 

 

 Total cholesterol, median (Q1, Q3)

4.3 (3.8, 4.9)

4.5 (4.3, 5.4)

6.2 (5.0, 6.8)

0.005

0.007

 TC <4.7, %

39/57 (68.4)

8/14 (57.1)

1/7 (14.3)

–

<0.001

 TC 4.8–5.1, %

7/57 (12.3)

0/14 (0.0)

0/7 (0.0)

 TC 5.2–6.1, %

5/57 (8.8)

4/14 (28.6)

0/7 (0.0)

 TC ≥6.2, %

6/57 (10.5)

2/14 (14.3)

6/7 (85.7)

 LDL, median (Q1, Q3)

3.0 (2.3, 3.4)

3.2 (2.3, 3.5)

3.9 (3.5, 5.2)

0.016

0.039

Cardiac and inflammatory biomarkers

 

 

 

 

 

 High sensitivity troponin I, median
(Q1, Q3)

2.5 (2.5, 3.4)

3.4 (2.8, 5.2)

4.1 (2.9, 7.1)

0.013

0.020

 hscTnI <2.5 ng/L, %

26/48 (54.2)

3/11 (27.3)

2/7 (28.6)

–

0.083

 hscTnI 2.5–45 ng/L

22/48 (45.8)

8/11 (72.7)

5/7 (71.4)

 hscTnI ≥45 ng/L

0/48 (0.0)

0/11 (0.0)

0/7 (0.0)

 High-sensitivity CRP, median (Q1, Q3) 1.5 (0.8, 4.0)

2.3 (0.8, 3.1)

1.0 (0.7, 3.6)

0.523

0.95

 hsCRP <1 mg/L

19/57 (33.3)

5/14 (35.7)

3/7 (42.9)

–

0.782

 hsCRP 1–3 mg/L

20/57 (35.1)

414 (28.6)

2/7 (28.6)

 hsCRP >3 mg/L

18/57 (31.6)

514 (35.7)

2/7 (28.6)

 Creatinine, median (Q1, Q3)

100.0 (89.5, 113.2)

98.5 (94.8, 115.0)

91.0 (79.0, 104.5) 0.702

0.610

Females
All (%)

108 (89.3)

9 (7.4)

4 (3.3)

 

 

Smoking

 

 

 

 

 

 Current smoker, %

2/108 (1.9)

0/9 (0.0)

0/4 (0.0)

–

0.241

 Ex-smoker, %

11/108 (10.2)

0/9 (0.0)

0/4 (0.0)

 Never smoker, %

95/108 (88.0)

9/9 (100.0)

4/4 (100.0)

 Diabetes, %

0/108 (0.0)

2/9 (22.2)

2/4 (50.0)

1.000

<0.0001

 Hypertension,§ %

24/108 (22.2)

7/9 (77.8)

3/4 (75.0)

<0.0001

<0.001

 Hyperlipidaemia, %

0/106 (0.0)

1/9 (11.1)

0/4 (0.0)

0.976

0.048

Lipid profiles

 

 

 

 

 

 Total cholesterol, median (Q1, Q3)

4.6 (3.8, 5.1)

5.4 (4.9, 6.1)

4.4 (4.3, 4.7)

0.07

0.031

 TC <4.7, %

54/105 (51.4)

2/9 (22.2)

3/4 (75.0)

–

0.883

 TC 4.8–5.1, %

13/105 (12.4)

2/9 (22.2)

0/4 (0.0)

 TC 5.2–6.1, %

18/105 (17.1)

2/9 (22.2)

1/4 (25.0)
0.042
 

0.082
 

 TC ≥6.2, %

20/105 (19.0)

3/9 (33.3)

0/4 (0.0)

 LDL, median (Q1, Q3)
Cardiac and inflammatory biomarkers

2.9 (2.4, 3.5)
 

4.0 (3.3, 4.2)
 

2.9 (2.6, 3.2)
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Table 3 Cardiovascular risk factors, markers of myocardial injury and inflammation by cardiovascular risk category*

Open access

Framingham risk score classification (lipid)†

P value for trend‡

Variable

Low

Intermediate

High

Increasing Two-sided

 High sensitivity troponin I, median
(Q1, Q3)

2.5 (2.5, 2.5)

2.8 (2.5, 4.1)

2.7 (2.6, 5.2)

0.003

0.006

–

0.003

 hscTnI <2.5 ng/L, %

74/92 (80.4)

3/7 (42.9)

1/4 (25.0)

 hscTnI 2.5–45 ng/L

17/92 (18.5)

4/7 (57.1)

3/4 (75.0)

 hscTnI ≥45 ng/L

1/92 (1.1)

0/7 (0.0)

0/4 (0.0)

 High-sensitivity CRP, median (Q1, Q3) 2.0 (0.9, 4.3)

6.9 (2.2, 10.3)

2.6 (2.5, 4.4)

0.012

0.022

 hsCRP <1 mg/L

1/9 (11.1)

0/4 (0.0)

–

0.128

0.047

0.047

30/107 (28.0)

 hsCRP 1–3 mg/L

34 (31.8)

2/9 (22.2)

3/4 (75.0)

 hsCRP >3 mg/L
 Creatinine, median (Q1, Q3)

43 (40.2)
76.0 (69.0, 85.5)

6/9 (66.7)
88.0 (75.0, 94.0)

1/4 (25.0)
91.0 (84.2, 99.5)

*Number of patients may not sum to the corresponding column totals where there are missing data for the cardiovascular risk factor/marker.
†Risk categories classified as low (<10%), intermediate (10%–19%) and high (≥20%).
‡P values for trend were calculated Jonckheere-Terpstra for continuous variables and Cochran-Armitage, or Cochran-Mantel-Haenszel tests,
approporiate, for categorical variables.
§Self-reported hypertension or measured systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg, or physician-
prescribed blood pressure-lowering medications.
hsCRP, high-sensitivity C-reactive protein; hscTnI, high-sensitivity cardiac troponin I; LDL, low-density lipoprotein.

Stored serum was available to measure hscTnI concentrations in 169 of the 200 participants. Despite using a
hscTnI assay, the majority had concentrations below the
limit of quantification at <2.5 ng/L (n=109/169, 65%).
Fifty-nine patients (n=59/169, 35%) had concentration
levels above the limit of quantification but below the 99th
centile upper reference limit. Serum hsCRP was measured
in 198 of the 200 participants. The median hsCRP was
2 mg/L (IQR 0.8–4.2 mg/L). Levels were numerically
higher in women compared with men (2.2 mg/L vs
1.5 mg/L). HsCRP categorised 75 (38%) patients as
having a high level (>3 mg/L) with 65 (33%) and 58
(29.3) at intermediate (1–3 mg/L) and low (<1 mg/L)
levels. Levels of hscTnI and hsCRP did not differ when
stratified by site (online supplemental table S2).
Using the sex stratified Framingham laboratory-based
risk score with lipids, the majority of the HIV population
was classified at low risk (83%) with 12% at intermediate
risk and 5% at high risk. Although sample sizes remained
limited when stratified by sex and risk category, the
prevalence of hypertension remained higher in women
compared with men (table 3) and as expected higher in
the intermediate and high-risk groups across the population (online supplemental table S3).
Association between hscTnI and hsCRP and traditional
cardiovascular risk factors were also evaluated (table 4).
The findings from cumulative logit models showed that
older patients were more likely to have higher hscTnI
levels (adjusted OR (aOR) per year: 1.05, 95% CI 1.01
to 1.09, p<0.011). Female patients, compared with male
patients, were identified as having lower hscTnI levels.
SBP of 140–159 mm Hg and SBP >160 mm Hg were associated with higher hscTnI concentrations (aOR 2.96
(95% CI 1.09 to 7.90, p=0.030) and 4.68 (95% CI 1.55

to 14.1, p=0.006), respectively) compared with those with
SBP <130 mm Hg. Our study did not find any strong associations between hsCRP and traditional cardiovascular
risk factors including age, hypertension, diabetes and
smoking. We also did not find any association between
SBP levels and hsCRP. Levels of hsCRP were higher for
HIV-patients with higher hscTnI levels. Study site—as a
surrogate for socioeconomic status—was not associated
with hscTnI or hsCRP.
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DISCUSSION
In this small, descriptive, cross-sectional study across two
sites in urban Kenya, we evaluated the prevalence of traditional cardiovascular risk factors. We also explored how
biochemical markers of inflammation and myocardial
injury are associated with traditional cardiovascular risk
factors in PLHIV. We make a number of observations.
First, in a relatively young population with HIV, some
traditional cardiovascular risk factors were common.
Smoking and diabetes rates, however, were low. Second,
using traditional risk estimation systems, the majority of
the young HIV population were categorised as low-risk for
future cardiovascular events. Third, across the majority of
patients, hsTnI values were below the limit of detection.
Fourth, in exploratory analysis we found no associations
between hsCRP levels and traditional cardiovascular risk
factors but did observe a positive association between
hscTnI levels and increasing age and higher SBP.
Some traditional cardiovascular risk factors were
common in the HIV population studied. Hypertension
was self-reported in one in five individuals and higher,
at one in three, when classified by office SBP measurehypertensives. Self-
reported
ment and/or use of anti-
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Table 3 Continued

Open access

Risk factor
Age (years)

High-sensitivity troponin I

High-sensitivity C-reactive protein

Model I
AOR (95% CI)

Model II
AOR (95% CI)

Model III
AOR (95% CI)

Model I
Adjusted Coef.
(95% CI)

Model II
Adjusted Coef.
(95% CI)

Model III
Adjusted Coef.
(95% CI)

1.05
(1.02 to 1.09,
p=0.004)

1.05
(1.01 to 1.09,
p=0.021)

1.04
(1.00 to 1.08,
p=0.032)

0.004
(−0.12 to 0.12,
p=0.952)

0.01
(−0.11 to 0.14,
p=0.860)

0.02
(−0.13 to 0.17,
p=0.775)

Sex

 

 

 

 

 

 

 Male

Reference

Reference

Reference

Reference

Reference

Reference

 Female

0.32
(0.14 to 0.70,
p=0.004)

0.39
(0.16 to 0.93,
p=0.035)

0.38
(0.17 to 0.84,
p=0.018)

1.66
(−0.85 to 4.18,
p=0.194

1.49
(−1.28 to 4.25,
p=0.290)

0.04
(−3.39 to 3.47,
p=0.980)

Study site

 

 

 

 

 

 

 AKUNH

Reference

Reference

Reference

Reference

Reference

Reference

 Coptic

1.08
(0.54 to 2.16,
p=0.832)

0.97
(0.48 to 1.99,
p=0.941)

0.91
(0.44 to 1.90,
p=0.805)

0.78
(−1.70 to 3.27,
p=0.536)

0.91
(−1.63 to 3.45,
p=0.481)

0.87
(−2.02 to 3.76,
p=0.553)

Hypertension

–

2.76
(1.36 to 5.63,
p=0.005)

–

–

−1.23
(−3.91 to 1.45,
p=0.366)

–

Diabetes

–

0.53
(0.06 to 3.37,
p=0.513)

–

–

0.41
(−6.24 to 7.06,
p=0.903)

–

Smoking

 

 

 

 

 

 

 Never smoker

Reference

Reference

–

–

Reference

–

 Former smoker

–

1.19
(0.51 to 2.70,
p=0.685)

–

–

−0.45
(−3.61 to 2.72,
p=0.781)

 

 Current smoker

–

1.36
(0.15 to 9.11,
p=0.762)

–

–

0.22
(−7.47 to 7.92,
p=0.954)

 

Systolic blood pressure

 

 

 

 

 

 

 SBP <130 mm Hg

Reference

–

Reference

–

–

Reference

 SBP 130–139 mm Hg

–

–

2.29
(0.87 to 5.87,
p=0.087)

–

–

−2.40
(−6.37 to 1.58,
p=0.235)

 SBP 140–159 mm Hg

–

–

3.08
(1.13 to 8.34,
p=0.026)

–

–

−3.47
(−8.13 to 1.19,
p=0.143)

 SBP >160 mm Hg

–

–

5.40
(1.75 to 16.6,
p=0.003)

–

–

−2.09
(−7.45 to 3.26,
p=0.441)

High-sensitivity CRP
mg/L

–

–

1.05
(1.01 to 1.10,
p=0.014)

–

–

–

High-sensitivity troponin-I  

 

 

 

 

 

 <2.50 ng/L

Reference

Reference

Reference

Reference

Reference

Reference

 2.50–3.02 ng/L

–

–

–

–

–

4.42
(0.78 to 8.07,
p=0.018)

 3.02–7.12 ng/L

–

–

–

–

–

1.20
(−2.43 to 4.84,
p=0.514)

 ≥7.12 ng/L

–

–

–

–

–

0.57
(−3.23 to 4.38,
p=0.766)
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Table 4 Relationship between baseline markers of myocardial injury and inflammation and traditional cardiovascular risk
factors, displayed as multivariable-adjusted ORs* for high-sensitivity cardiac troponin I and multivariable-adjusted mean
differences† for hsCRP

Open access

High-sensitivity troponin I

Risk factor
Creatinine mg/L

High-sensitivity C-reactive protein

Model I
AOR (95% CI)

Model II
AOR (95% CI)

Model III
AOR (95% CI)

Model I
Adjusted Coef.
(95% CI)

Model II
Adjusted Coef.
(95% CI)

Model III
Adjusted Coef.
(95% CI)

1.00
(0.98 to 1.03,
p=0.671)

1.01
(0.99 to 1.03,
p=0.399)

1.01
(0.99 to 1.04,
p=0.177)

−0.01
(−0.05 to 0.02,
p=0.568)

−0.01
(−0.04 to 0.03,
p=0.644)

−0.11
(−0.20 to −0.03,
p=0.010)

*Cumulative logit model with high-sensitivity troponin-I response as myocardial injury marker. Bold p values indicate statistical significance (p<0.05). Model I adjusts
for age, sex, creatinine and study site; Model II as for Model I plus history of hypertension, diabetes and smoking status; Model III as Model I plus systolic blood
pressure and hsCRP levels.
†Linear regression with high-sensitivity C-reactive protein (hsCRP) response as inflammation marker. Bold p values indicate statistical significance (p<0.05). Model
I adjusts for age, sex and creatinine; Model II as for Model I plus history of hypertension, diabetes and smoking status; Model III as Model I plus systolic blood
pressure and hsCRP levels.
AKUHN, Aga Khan University Hospital, Nairobi; AOR, adjusted OR; Coef., coefficient as multivariable mean difference; Coptic, Coptic Hope Center for Infectious
Diseases.

dyslipidaemia was low at 1 in 20 but much higher when
based on total cholesterol concentration >6.1 mmol/L
(19%). This discordance likely reflects individuals being
unaware of their cholesterol status. Smoking and diabetes
rates, however, remained relatively low in contrast to
PLHIV in high-income countries.22 Our prevalence rates
of traditional cardiovascular risk factors are in agreement with other studies from the sub-Saharan African
region23–25 and discordant to those evaluating PLHIV in
high-income settings.22 26 While North American/European studies contribute to most of the evidence evaluating CVD in HIV, the region only hosts 6% of the global
HIV population compared with 75% for sub-
Saharan
Africa.27 28 PLHIV in sub-
Saharan Africa and North
America/Europe are different by virtue of the factors
associated with HIV acquisition. HIV remains firmly established in the general population in sub-Saharan African
but overwhelmingly affects men who have sex with men
and intravenous drug users in North America/Europe.29
These differences probably account for regional discordance in the association between HIV status and prevalence of cardiovascular risk factors that has been observed
in the published literature. Positive associations in North
America/Europe either become null or even reverse in
sub-Saharan Africa.22–26 30–33
Using the sex stratified Framingham laboratory-
based risk score, the overwhelming majority of the HIV
population was classified at low risk (83%) with 12% at
intermediate risk and 5% at high risk. Similar risk categorisations were obtained when using the Framingham
non-laboratory-based risk scores. All established cardiovascular risk estimation systems—predominantly developed in high-income countries and not accounting for
HIV status are highly influenced by age. As such, our
findings likely reflect the younger age distribution in
our study.12 34 Whether this estimation of low-risk, using
generalised risk scores developed predominantly in high-
income countries, reflects the observed cardiovascular
risk of HIV individuals in sub-
Saharan Africa remains
uncertain.
Previous studies have shown how biochemical markers,
such as hsCRP and hscTnI, may hold promise in
Ahmed HA, et al. BMJ Open 2022;12:e062352. doi:10.1136/bmjopen-2022-062352

improving cardiac risk estimation systems.35 Our study
showed that the majority of individuals had undetectable
levels of hscTnI with only one in three patients demonstrating levels above the limit of detection. Previous
studies in high-income settings have shown that during
acute HIV infection, troponin levels are higher but drop
threefold once viremic control is achieved.36 A large
proportion of our patients were established on ART and
with the duration of diagnosis to study recruitment being
nearly 12 years. Two studies showed contrasting results
when evaluating the association between troponin levels
and presence of coronary plaques, with results primarily
applicable to men with HIV in non-endemic regions.37 38
Levels of hsCRP, suggestive of underlying inflammation,
were high in this study with women having higher concentrations. Whether higher baseline hsCRP levels relate to
increased risk of cardiovascular events in HIV, however,
remains uncertain with contrasting data in the published
literature.39 40 Higher levels of hsCRP in people with
HIV is biologically plausible and supported by previous
studies,28 41 but may not just be reflective of vascular
disease.42 As such the specificity of hsCRP for CVD in
PLHIV may be low.
Our study showed, hscTnI levels were higher in men,
associated with increasing age, measured SBP and
reported history of hypertension. This is similar to what
has been observed in the general population.43 44 However,
surprisingly, in our study, much of the population had
troponin concentrations below the limit of quantification
despite using a high-sensitivity assay likely reflective of a
younger population. Unlike in the general population,45
we did not show any robust association between hsCRP
and traditional cardiovascular risk factors. This may
reflect the younger age of our population with previous
studies showing higher hsCRP values in the elderly.46
This is one of the few studies that has quantified the
prevalence of cardiovascular risk factors and explored
their association with biochemical markers of inflammation and myocardial injury in HIV populations from two
distinct centres in urban Kenya. However, several limitations should be considered. First, our study was cross-
sectional and we were unable to evaluate the associations
9
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CONCLUSIONS
In conclusion, we show that while some traditional
cardiovascular risk factor prevalences remain high in HIV
populations in sub-Saharan Africa, important ones such
as smoking are low. This is in contrast to HIV populations
in non-endemic regions.22 The majority of PLHIV—using
traditional risk estimation systems—have a low estimated
CVD risk likely reflecting a younger aged population
predominantly consisting of women. While hscTnI values
were associated with increasing age and higher blood
pressure, no associations between hsCRP levels and traditional cardiovascular risk factors were observed.
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between novel biochemical markers and future cardiovascular events. Second, HIV populations in our study were
recruited across two centres in Nairobi, representing a
predominantly urban population. Whether our findings
are generalisable to rural populations remains uncertain. Third, given resource limitations, we did not study
age-matched and sex-matched non-HIV populations and
were limited to a finite choice of biochemical biomarkers.
As such our study is unable to comment on associations
between a wider range of biochemical markers and cardiovascular risk factors in the general population and how
these may differ to those infected with HIV. For the same
reason we were also unable to measure metric if infection
control (viral load and CD4 count) at the time of recruitment. Fourth, some of the risk factors such as diabetes
status depended on self-reporting—as such, the absence
of associations may reflect exposure misclassification.
Lastly, we cannot exclude the possibility that associations
between biomarkers and outcomes may in part be due to
residual confounding or unmeasured confounders.
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